文献速递免疫规划慢病防控与筛查

免疫功能低下人群流感疫苗免疫原性提升策略

Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
PubMed 文献 · Vaccine · 2021-01-07

免疫功能低下者(移植患者、接受免疫抑制剂治疗者及其他免疫缺陷者)对标准流感疫苗应答较低且常不具保护性。本文综述提升该人群流感疫苗免疫原性的策略,包括佐剂疫苗、高剂量疫苗、加强剂量、皮内接种及暂时停用免疫抑制剂。高剂量三价灭活裂解流感疫苗(IIV3-HD)在HIV患者、移植患者及因炎症性疾病接受免疫抑制剂治疗者中显示出比标准剂量疫苗更强的体液应答且安全性相当,部分科学学会认为其可作为优选,但仍需更大规模随机对照研究验证。

要点

  • 免疫功能低下者推荐接种灭活流感疫苗,但标准剂量应答低且常不具保护性。
  • 高剂量三价灭活裂解疫苗(IIV3-HD)在HIV、移植及免疫抑制剂治疗者中抗体应答更强。
  • IIV3-HD安全性与其他增强策略相当,但需更大规模随机对照研究验证。

核心结论

  • 高剂量三价灭活裂解流感疫苗(IIV3-HD)是提升HIV患者、移植患者及接受免疫抑制剂治疗者疫苗应答的领先策略之一,部分科学学会认为其可作为该人群的优选。

研究设计与样本

  • 本文为综述,回顾旨在提升免疫功能低下人群流感疫苗免疫原性的策略,涵盖佐剂疫苗、高剂量疫苗、加强剂量、皮内接种及暂时停用免疫抑制剂。

主要发现

  • 免疫功能低下人群对标准流感疫苗的应答较低且常不具保护性。
  • 多项研究显示IIV3-HD在HIV患者、移植患者及因炎症性疾病接受免疫抑制剂治疗者中诱发的体液应答强于现有标准剂量三价疫苗,且安全性相当。

关键数值与推荐

  • 推荐移植患者、接受免疫抑制剂治疗者及其他免疫缺陷者接种灭活流感疫苗。
  • 部分科学学会指出高剂量流感疫苗可作为免疫功能低下患者的优选。

临床怎么用

  • 对移植患者、接受免疫抑制剂治疗者及其他免疫缺陷者,可考虑选用高剂量三价灭活裂解流感疫苗(IIV3-HD)以提升免疫应答。

局限性

  • 需更大规模随机对照研究验证IIV3-HD及其他增强疫苗和接种策略在免疫功能低下人群中的相对免疫原性与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunocompromised individuals are at high risk of severe illness and complications from influenza infection. For this reason, immunization using inactivated influenza vaccines is recommended for transplant patients, individuals receiving immunosuppressant treatments, and other persons with immunodeficiency. However, these immunocompromised populations are more likely to have lower and non-protective responses to annual vaccination with a standard influenza vaccine. Here, we review strategies aimed to improve the immunogenicity of influenza vaccines in immunocompromised populations. The different strategies employed have included adjuvanted vaccines, high-dose vaccines, booster doses, intradermal vaccination, and temporary discontinuation of immunosuppressant treatment regimens. High-dose trivalent, inactivated, split-virus influenza vaccine (IIV3-HD) is so far one of the leading strategies for improving vaccine responses in HIV patients, transplant patients, and persons receiving immunosuppressant therapies for inflammatory diseases. Several studies in these populations have shown stronger humoral responses with IIV3-HD than existing standard-dose trivalent vaccine, and comparable safety. Accordingly, some scientific societies have stated that high-dose influenza vaccine could be a preferred option for immunocompromised patients. However, larger randomized controlled studies are needed to validate relative immunogenicity and safety of IIV3-HD and other enhanced vaccines and vaccination strategies in immunocompromised individuals.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Caldera F, Mercer M, Samson SI, et al. Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity. Vaccine. 2021. PMID: 33422377. doi:10.1016/j.vaccine.2020.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。